Precure, LLC aims to identify biological changes that occur before disease symptoms emerge by linking molecular data with longitudinal clinical information.
Approach:
Data generation: The initiative plans to generate proteomic and genomic data from one million biospecimens and connect these data with clinical information collected over several years.
Analysis: Artificial intelligence and large-scale data analytics will be used to identify patterns and potential biological insights.
Partnership: Mayo Clinic will hold a majority stake; Thermo Fisher Scientific will be a founding partner and minority owner, contributing proteomics expertise and technologies, including Olink Explore HT and Thermo Scientific Orbitrap Mass Spectrometry.
Key Findings:
Precure is a newly launched company formed by Mayo Clinic and Thermo Fisher Scientific.
The planned dataset is intended to support research across cancer, cardiometabolic disease, neurological disorders, and immune-mediated conditions.
The company will complement Mayo Clinic’s investigator-led Precure Research program by providing infrastructure, scale, and external collaborations.
Mayo Clinic says financial returns from the venture will be reinvested in its patient care, research, and education missions.
Interpretation:
The initiative is designed to build population-level molecular datasets to study disease development before symptoms appear and support development of diagnostics, therapeutics, and other healthcare technologies.
Limitations:
The context describes plans and intended uses; it does not report completed data generation or research outcomes.
No study methods, participant characteristics, or performance results are provided.
